Connective Tissue Massage and Progressive Relaxation in Primary Dysmenorrhea
9. června 2026 aktualizováno: Raziye Şavkın, Pamukkale University
The Effectiveness of Connective Tissue Massage and Music-Based Progressive Muscle Relaxation for Primary Dysmenorrhea
This randomized controlled clinical trial aims to investigate the effects of Connective Tissue Massage (CTM) and music-based Progressive Muscle Relaxation Training (PMRT) on pain, pain threshold, analgesic use, and menstruation-related symptoms in women with primary dysmenorrhea.
Participants will be randomly assigned to CTM, music-based PMRT, or control groups.
Interventions will be applied during the 1st and 2nd menstrual cycles following the baseline assessment.
No intervention will be applied between the 2nd and 3rd menstrual cycles, and follow-up assessments will be conducted during the 3rd cycle.
Outcomes including pain severity, pain threshold, menstrual symptoms, attitudes toward menstruation, functional and emotional impact, and pain catastrophizing will be evaluated across menstrual cycles.
Participant satisfaction and adherence to the interventions will also be assessed.
Přehled studie
Postavení
Zatím nenabíráme
Podmínky
Typ studie
Intervenční
Zápis (Odhadovaný)
36
Fáze
- Nelze použít
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Ne
Popis
Inclusion Criteria:
- Having a diagnosis of primary dysmenorrhea made by a Gynecology and Obstetrics specialist
- Being between 18-30 years of age
- Being nulliparous
- Having a regular menstrual cycle (28 ± 7 days)
- Having menstrual pain intensity greater than 4 cm on the Visual Analog Scale for the last 6 months
- Voluntarily agreeing to participate in the study
Exclusion Criteria:
- Having been diagnosed at least 6 months prior with gastrointestinal, urogynecological, autoimmune, or psychiatric diseases and/or chronic pain syndromes
- Having any neurological or systemic disease
- Having a history of childbirth or previous pregnancy
- Being pregnant
- Using an intrauterine device (IUD)
- Having any pelvic pathology or history of pelvic surgery
- Chronic use of medications, including oral contraceptives or antidepressants
- Currently receiving anti-inflammatory, analgesic, or psychotherapeutic drug treatment
- Having irregular menstrual cycles (<21 or >35 days and/or cycle variation >4 days)
- Presence of pathology indicating secondary dysmenorrhea
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Kontrolní skupina
|
|
|
Experimentální: Connective Tissue Massage Group
|
Connective tissue manipulation will be applied to the sacrolumbar, lower thoracic, abdominal, and anterior pelvic regions.
The intervention will be performed five days per week from the estimated ovulation day (cycle length minus 14 days) until the onset of the next menstrual period.
|
|
Experimentální: Music-Based Progressive Muscle Relaxation Training Group
|
Participants will receive music-based Progressive Muscle Relaxation Training (PMRT) using recordings from the Turkish Psychological Association's Relaxation Exercises CD.
At the beginning of the study, participants will be informed face-to-face about the purpose, procedure, and breathing techniques of PMRT, and the first session will be conducted in person.
Thereafter, PMRT sessions will be performed using the approved audio recordings.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pain Intensity
Časové okno: At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
Participants' menstrual pain intensity will be assessed using the Visual Analog Scale (VAS).
Participants will be asked to rate the average pain intensity experienced during the first two days of menstruation, the average pain intensity experienced throughout the menstrual period, and the pain intensity experienced at its worst during menstruation.
The VAS is widely used in clinical practice and scientific research to assess pain perception.
Scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Higher scores indicate greater pain intensity and therefore a worse outcome.
|
At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
|
Pain Threshold
Časové okno: At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
Pain threshold assessment will be performed using a JTech Medical Commander Algometer.
Measurements will be taken using a 1 cm² pressure probe, with the algometer held perpendicular to the measurement site.
Assessments will be conducted at six different points: 4 cm to the right and left of the umbilicus (points 1 and 2), 4 cm below these two points (points 3 and 5), 4 cm below the umbilicus (point 4), and the midpoint of the spinous processes of the S2-S4 vertebrae (point 6).
Two measurements will be obtained from each point, with a 30-second rest interval between measurements.
The average of the two readings will be calculated and recorded in lbs/cm².
|
At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
|
Menstrual Symptom Scale
Časové okno: At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
The Menstrual Symptom Scale was used to assess menstrual pain and related symptoms.
The scale consists of 22 items evaluating menstruation-related symptoms and is rated on a five-point Likert scale ranging from never to always.
The scale comprises three subscales: items 1-13 represent the "Negative Effects/Somatic Complaints" subscale, items 14-19 represent the "Menstrual Pain Symptoms" subscale, and items 20-22 represent the "Coping Strategies" subscale.
An increase in the mean score indicates a higher severity of menstrual symptoms within the corresponding subscale.
|
At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
|
Menstrual Attitude Scale
Časové okno: At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
The scale is based on the assumption that expectations regarding physiological and emotional symptoms before or during menstruation may influence behaviors during this period.
It consists of a total of 33 items across five categories: menstruation as a debilitating phenomenon (12 items), menstruation as a disturbing phenomenon (6 items), menstruation as a natural phenomenon (5 items), anticipation/perception of menstruation (5 items), and denial of the effects of menstruation (7 items).
Each item is rated on a five-point scale ranging from 1 (strongly disagree) to 5 (strongly agree).
Higher scores on the scale indicate a more positive attitude toward menstruation.
|
At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
|
Functional and Emotional Dysmenorrhea Scale
Časové okno: At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
Functional and Emotional Dysmenorrhea Scale is a Likert-type instrument used to assess dysmenorrhea in terms of functional and emotional aspects.
It consists of 14 items and 2 subscales.
Higher scores indicate a greater level of functional and emotional impact of dysmenorrhea on individuals.
|
At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
|
Pain Catastrophizing Scale
Časové okno: At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
The Pain Catastrophizing Scale will be used to assess catastrophizing related to menstrual pain during the last menstrual period.
The scale consists of 13 items and 3 subscales (helplessness, magnification, and rumination).
Participants will be asked to rate the extent to which they experienced each of the 13 thoughts or feelings during menstrual pain on a 5-point scale ranging from 0 (not at all) to 4 (always).
|
At baseline, immediately post-intervention (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period), and during the subsequent menstrual cycle follow-up.
|
|
Intervention Satisfaction
Časové okno: After the intervention period (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period).
|
Patients' satisfaction with the Connective Tissue Massage or Music-Based Progressive Muscle Relaxation Training interventions will be assessed using a 10-cm Visual Analog Scale (VAS) through two questions.
Q1: How satisfied were you with the overall treatment you received?
(0: Not at all satisfied - 10: Extremely satisfied) Q2: Would you recommend this treatment and/or advice to someone you know who suffers from menstrual pain?
(0: Definitely would not recommend - 10: Definitely would recommend)
|
After the intervention period (the intervention period extending from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period).
|
|
Intervention Adherence
Časové okno: During the intervention period (from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period).
|
Participants' adherence to Connective Tissue Manipulation sessions will be recorded by the researcher who administers the intervention.
Participants will be asked to record their Music-Based Progressive Muscle Relaxation Training sessions in a relaxation diary.
Adherence will be calculated as the percentage of completed sessions relative to the planned number of sessions.
Compliance will be classified as good (≥80%), moderate (50-79%), or low (<50%) adherence.
|
During the intervention period (from the estimated ovulation day [cycle length minus 14 days] until the onset of the subsequent menstrual period).
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Spolupracovníci
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Odhadovaný)
15. června 2026
Primární dokončení (Odhadovaný)
1. března 2027
Dokončení studie (Odhadovaný)
1. června 2028
Termíny zápisu do studia
První předloženo
21. května 2026
První předloženo, které splnilo kritéria kontroly kvality
9. června 2026
První zveřejněno (Aktuální)
15. června 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
15. června 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
9. června 2026
Naposledy ověřeno
1. června 2026
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- E-60116787-020-776510
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .